CNS drugs prominent in NZ's Q2 new drug listings

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.317, 2001-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New drug listings for reimbursement in New Zealand

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 352, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Regulation of microglia - potential new drug targets in the CNS

By Aldskogius Håkan

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 6, 2001-12 ,pp. : 655-668

Informa Healthcare

Access to resources Recommend Favorite

Multiple drugs: CNS depression following drug poisoning: 3 case reports

Reactions Weekly, Vol. 1, Iss. 1411, 2012-01 ,pp. : 32-33

Adis International

Access to resources Recommend Favorite

Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs

Current Medicinal Chemistry, Vol. 21, Iss. 23, 2014-08 ,pp. : 2599-2609

Bentham Science Publishers

Access to resources Recommend Favorite

CNS Drugs III: Psychotherapeutics

By Marsden C.A. Stanford S.C.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 8, 2000-08 ,pp. : 1923-1929

Informa Healthcare

Access to resources Recommend Favorite